Eli Lilly & (LLY) Stock
Major pharmaceutical group with diabetes and obesity medicines. Here's the price, business snapshot, and what's worth knowing about Eli Lilly & in September 2026.
Eli Lilly and Company (LLY) is a major US pharmaceutical group with a broad portfolio spanning diabetes, oncology, immunology and neuroscience. With a market capitalisation around $756.8bn, Lilly is known for strong commercial medicines such as GLP-1 and dual-agonist therapies that have driven recent sales growth, alongside a diversified R&D pipeline. Investors should know Lilly combines steady cash-generating marketed products with growth from newer launches and late‑stage candidates, but faces typical sector risks: regulatory review, patent expiries, pricing scrutiny and competition. Financials can be resilient but are sensitive to trial outcomes and reimbursement decisions. As general information, this summary is educational not personal financial advice — returns are not guaranteed and values can fall as well as rise. Prospective investors should consider their objectives, time horizon and risk tolerance, and may wish to consult an authorised financial adviser before investing.
Why It’s Moving
Lilly’s growth story stays in focus as earnings strength and pipeline progress keep shares active
- Lilly’s late-summer momentum is being driven by a strong second-quarter update, where revenue and earnings beat expectations and management lifted full-year guidance, reinforcing confidence in the company’s growth runway.
- Investor attention remains centered on the obesity and diabetes franchise, as demand for Zepbound and Mounjaro continues to support sales strength and offset concerns about valuation.
- Recent regulatory and pipeline progress has added to the bullish backdrop, including updates tied to expanded approvals and advancing late-stage assets that could broaden Lilly’s growth beyond incretin therapies.
Lilly’s growth story stays in focus as earnings strength and pipeline progress keep shares active
- Lilly’s late-summer momentum is being driven by a strong second-quarter update, where revenue and earnings beat expectations and management lifted full-year guidance, reinforcing confidence in the company’s growth runway.
- Investor attention remains centered on the obesity and diabetes franchise, as demand for Zepbound and Mounjaro continues to support sales strength and offset concerns about valuation.
- Recent regulatory and pipeline progress has added to the bullish backdrop, including updates tied to expanded approvals and advancing late-stage assets that could broaden Lilly’s growth beyond incretin therapies.
Sixth Month Growth Performance
When is the next earnings date for Eli Lilly & Co (LLY)?
The next earnings date for LLY is expected on October 29, 2026. It should cover third-quarter 2026 results. The company has already scheduled a Q3 2026 earnings call for that date, which aligns with its typical late-October reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Eli Lilly's stock, expecting its value to rise in the future.
Financial Health
Eli Lilly is demonstrating strong profits, cash flow, and revenue, indicating robust financial performance.
Dividend
Eli Lilly's low dividend yield of 0.56% indicates limited income from dividends. If you invested $1000 you would be paid $5.46 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Pipeline-led growth
Late-stage candidates and recent product roll-outs can boost revenue, though outcomes and timelines are uncertain and can affect share performance.
Global commercial reach
A wide geographic footprint helps diversify sales, but reimbursement policies and pricing pressure vary by market and may impact returns.
R&D and innovation
Heavy R&D investment fuels long-term potential, while the opposite side of the coin is the cost and risk of trials and regulatory review.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
